Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Abroad (travel likely)RecruitingPHASE2
Conditions
Multiple Myeloma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Cross Cancer Institute, Edmonton, Alberta, Canada
Contact: Study coordinator (Farzana Khawaja, RN) · Farzana.Khawaja@cancercarealberta.ca · 780 989-5970Contact: Study coordinator (Doris Tengu Inyam Fombang) · doristengu.inyamfombang@cancercarealberta.caContact: Principal Investigator (Irwindeep Sandhu, MD)NL Health Services, St. John's, Newfoundland and Labrador, Canada
Contact: Principal Investigator (Debra Bergstrom, MD)QEII Health Science Centre, Halifax, Nova Scotia, Canada
Contact: Principal Investigator (Alfredo De la Torre, MD)London Health Sciences Centre, London, Ontario, Canada
Princess Margaret Hospital, Toronto, Ontario, Canada
Contact: Principal Investigator (Guido Lancman, MD, MSc)Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada
Contact: Study coordinator (Marie-Pier Lecours-Cyr) · mplecours-cyr.hmr@ssss.gouv.qc.ca · 514-252-3400Contact: Principal Investigator (Richard LeBlanc, MD)McGill University Health Centre, Montreal, Quebec, Canada
Contact: Principal Investigator (Micahel Sebag, MD)
Study leads
Martha Louzada, MD, MSc
Principal Investigator
London Health Sciences Centre